dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
dQ&A Presented Three Abstracts at EASD 2023 | dQ&A
We partnered with LMC to connect real-world patient experience insights with validated clinical data for patients across the diabetes spectrum.
This study provides real-world evidence on hypoglycemia prevalence, its effects on people, and the implications for HCP & diabetes manufacturers.
Our research finds Mounjaro patients report health benefits but face confusion and frustration during therapy initiation.
Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
A dQ&A-CeQur study in Clinical Diabetes finds 2 months on the CeQur Simplicity insulin patch boosts patient satisfaction, cuts burden, and lifts well-being.
dQ&A research reveals primary care challenges in adopting diabetes tech, highlighting needs for CGM training, simpler tools, and better industry support.
This article reports results of a survey of patients and health care providers regarding their experiences of and challenges with the use of basal insulin.
